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A liquid chromatographic–mass spectrometric assay with
atmospheric pressure chemical ionization for quantification of
ondansetron and its main metabolite 8-hydroxyondansetron in
human plasma was presented. The enantiomeric separation was
achieved on a Chiralcel OD-R column containing cellulose tris-
(3,5-dimethylphenylcarbamate). The validation data were within
the required limits. The assay was successfully applied to authentic
plasma samples. Quantitative results from postoperative patients
receiving ondansetron demonstrated a great interindividual
variability in postoperative plasma drug concentrations, the
metabolites were not detected in their unconjugated form.
A wide variation in the S-(+)-/R-(–)-ondansetron concentration
ratio between 0.14 and 7.18 is indicative for a stereoselective
disposition or metabolism. In further studies CYP2D6 and
CYP3A4 genotype dependent metabolism of ondansetron
enantiomers as well as of co-administered drugs and clinical
efficacy of the medication should be tested.
Introduction
Ondansetron, (±)-9-methyl-3-[(2-methylimidazol-1-
yl)methyl]-2,3-dihydro-1H-carbazol-4-one (Figure 1), is a
highly selective and potent 5-hydroxytryptamine type 3 (5-
HT3) receptor antagonist. It is effective in the treatment of
postoperative nausea and vomiting (PONV) as well as during
cancer chemotherapy and radiotherapy, and it has reported
anxiolytic and neuroleptic properties (1–4).
Ondansetron has a short plasma half-life of approximately 3
to 5 h (5,6). Between 70% and 76% of ondansetron is protein
bound, and it is extensively metabolized in the liver by the
hydroxylation of the indole ring to 7- and mainly 8-hydroxy-
ondansetron (40%) followed by glucuronide or sulfate conju-
gation (7); 6-hydroxylation and demethylation are minor routes
of metabolism. In terms of overall ondansetron elimination,
CYP3A4 plays the predominant role, but primary hydroxylation
is also done via CYP2A6 and 1A2 (8–10). Approximately 5% is
excreted unchanged in the urine. Although some of the non-
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Abstract
Figure 1. Structures of ondansetron and its main metabolite 8-hydroxy-
ondansetron.
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conjugated metabolites have pharmacological activity, their
plasma concentrations are probably too low to contribute to
the biological activity of ondansetron.
In pharmacokinetic studies ondansetron concentration was
measured using achiral procedures. However, ondansetron is
usually be marketed as a racemic mixture of the R-(−)- and S-
(+)-enantiomers. Considering the parallel rightward displace-
ment of the 2-methyl-5-HT concentration response curve at
the longitudinal smooth muscle of the Guinea-pig ileum, the
potency of R-(−)-ondansetron was approximately eightfold
higher than that of S-(+)-ondansetron (11). Also, administra-
tion of R-(−)-ondansetron avoided adverse effects including
headache, constipation, and increases in transaminase levels,
which are associated with the administration of racemic
ondansetron (12).
Besides a number of achiral procedures for the measurement
of ondansetron in plasma samples (13–17), only a few chiral
methods have been reported for the determination of R-(−)-
and S-(+)-ondansetron up to now. These include high
performance capillary electrophoresis with heptakis-(2,6-di-
O-methyl)-β-cyclodextrin as a mobile phase modifier (18) as
well as high-performance liquid chromatography coupled with
ultraviolet-spectroscopy (HPLC–UV) using a Chiralcel OD
column (19) or a Chiracel OD-R column (20). Recently a liquid
chromatographic–tandem mass spectrometric (LC–MS–MS)
procedure using an ovomucoid column was developed for the
enantioselective measurement of ondansetron in human
plasma samples (21).
The aim of the present work was the development of a chiral
LC–MS–MS procedure for the quantitative determination of
R-(−)- and S-(+)-ondansetron together with R-(−)- and S-(+)-
8-hydroxyondansetron in postoperative patients receiving an
antiemetic medication to proof possible stereoselective
pharmacokinetic differences between both enantiomers.
Experimental
Chemicals
The (+)- and (–)-enantiomers of ondansetron and 8-hy-
droxyondansetron were a gift of GlaxoSmithKline (München,
Germany). Racemic propanolol was purchased from LGC Pro-
mochem™ (Wesel, Germany). Triethylamine (TEA) was ob-
tained from Fluka (Neu-Ulm, Gemany), ethanol absol. and
sodium hydroxide were from Merck (Darmstadt, Germany),
and 95% n-hexane and dichloromethane were from J.T. Baker
(Deventer, Netherlands).
Standard solutions and calibration samples
A methanolic stock solution containing R-(−)- and S-(+)-
ondansetron and R-(−)- and S-(+)-8-hydroxyondansetron as
well as a stock solution containing (±)-propanolol were pre-
pared in methanol in concentrations of 10 µg/mL. All solutions
were stored at –20°C. For calibration mixed spiked plasma
samples were created in following concentrations for each
enantiomer: 2.5, 10, 25, 50, 75, 100, 200, and 250 ng/mL.
Sample preparation
A mixture of 0.2-mL plasma sample, internal standard
solution (10 µL of propanolol. in a concentration of 10 µg/mL
methanol), and 0.2 mL of borate buffer (pH 9) was extracted
with 1 mL dichloromethane. After centrifugation (4000 × g for
8 min), the organic phase was evaporated to dryness under a
stream of nitrogen at 50°C. The residue was dissolved in 0.1 mL
of HPLC mobile phase A, and a 10-µL aliquot was used for
chromatography.
Chromatographic and MS equipment and conditions
An LC–MS–MS system consisting of an Agilent (Waldbronn,
Germany) 1100 HPLC system (binary pump, degasser, and
autosampler) coupled with an Applied Biosystems (Darmstadt,
Germany) API 2000 triple-quadrupole MS was used for analysis
performing atmospheric pressure chemical ionization (LC–
APCI-MS). The enantiomeric separation was achieved on a
Chiralcel OD-R column (10 µm, 250 × 46 mm; Daicel Chemical
Industries, Illkirch, France) containing cellulose tris-(3,5-
dimethylphenylcarbamate) as chiral selector. LC separation
was performed using mobile phase A (water/acetonitrile, 98:2,
5 mM ammonium formate) and mobile phase B
(water/acetonitrile, 10:90, 5 mM ammonium formate; pH 3.5)
in a gradient program with a total flow of 400 µL/min (binary
system): 0–15 min: 85% A; 15–16 min: 85% A→ 0% A; 16–21
min: 0% A; 21–22 min: 0% A → 85% A; 22–30 min: 85% A.
From the molecular ions ([M+H+]) following transitions were
detected in positive multiple reaction monitoring: ondansetron
m/z 293.8→ 170.0, 184.0; 8-hydroxyondansetron m/z 309.9→
185.9, 199.8; propanolol (IS) m/z 259.95→ 116.1, 182.9 (quan-
titation ions underlined).
For quantification, peak-area ratios of the analytes to the in-
ternal standard were calculated as a function of the concen-
tration of the substances.
Validation protocol
Selectivity. For evaluation of method selectivity, blank
plasma samples from different sources were prepared as de-
scribed, but without adding any analyte or internal standard
mix (n = 6). Additionally, six samples were analyzed from pa-
tients receiving the same medication with metoclopramide
instead of ondansetron. Furthermore, blank samples were an-
alyzed to check the absence of analyte ions in the respective
peaks of the internal standard (n = 2).
Linearity. For calibration, plasma samples were spiked with
the R-(−)- and S-(+)-enantiomers of ondansetron and 8-hy-
droxyondansetron in concentrations from 2.5 to 250 ng/mL
and processed as described (n = 6). Using mean values, cali-
bration curves were checked for variance homogeneity (F-
Test) and for linearity (Mandel-Test).
Sensitivity. The LOD was defined as the analyte concentra-
tion at which the signal-to-noice ratio was 3. The LOQ was de-
fined as three times the LOD.
Precision data and recoveries. Additionally, spiked quality
control (QC) plasma samples (high = 100 ng/mL, middle = 50
ng/mL, and low = 10 ng/mL) were prepared and analyzed in
each series. Absolute recoveries were calculated comparing
the peak areas of all analytes after extraction with the results
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after injection of the same concentration (50
ng/mL) directly without extraction, which was de-
fined as 100%.
Matrix effects. Matrix-related ionization effects
were evaluated by comparing analyte responses of
post-extraction spiked samples to those of spiked
samples representing 100% recovery. Five repli-
cates at low (10 ng/mL) and high (100 ng/mL) con-
centration were analyzed.
Stability studies. For the evaluation of the enan-
tiometic stability, blank plasma samples were spiked
with 50 ng/mL (each enantiomer in single tests)
and incubated at 25°C for 24 h, then extracted and
analyzed as described. Furthermore long-term sta-
bility of all analytes was tested at –20°C for three
months as well as the autosampler stability after ex-
traction (ready-to-inject samples) at 20°C for 24 h.
The freeze/thaw stability was evaluated after three
complete freeze/thaw cycles on consecutive days.
The analytes were considered stable when 85–115%
of the initial concentration was found.
Application of the method
After approval by the local ethics committee and
written informed consent plasma concentrations
of the R-(−)- and S-(+)-enantiomers of ondansetron
as well as of 8-hydroxyondansetron were analyzed
in patients recovering from major abdominal
surgery. General anesthesia was conducted using a
standardized protocol: 2 mg/kg propofol, 0.2 mg
fentanyl, and cis-atracurium for induction and
remifentanil, isoflurane, and cis-atracurium for
maintenance of anesthesia. About 30 min before
termination of anesthesia, 4 mg ondansetron was
given i.v. followed by an analgesic loading dose of
dipyrone 1 g and piritramid 0.08 mg/kg.
Blood samples were obtained with ethylenedi-
aminetetraacetic acid (EDTA) as anticoagulant be-
tween 30 and maximal 180 min after application of
ondansetron. Whole blood was centrifuged and
plasma was separated and frozen until analysis at
–80°C.
Results and Discussion
The method’s selectivity was tested by comparing
the chromatograms of six different blank plasma
samples with corresponding spiked plasma. Also,
two blank samples were analyzed to check the ab-
sence of analyte ions in the respective peaks of the
internal standard. Additionally, six samples were
analyzed from patients recovering from major ab-
dominal surgery and receiving the same medication
with metoclopramide instead of ondansetron. No
interferences due to matrix or other potentially in-
terfering compounds were found.
Figure 2. Chromatogram of a blank sample (A), a standard sample containing 100 ng/mL
ondansetron and 8-hydroxyondansetron enantiomers (B), and finally of an authentic plasma
sample containing S-(+)-ondansetron (55.2 ng/mL) and R-(–)-ondansetron (45.3 ng/mL) (C).
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A complete enantiomeric separation of the R-(−)- and
S-(+)-enantiomers of ondansetron and the racemic internal
standard was obtained on a cellulose tris-3,5-dimethyl-
phenylcarbamate OD-R column using an ammonium formate
buffer/acetonitrile as mobile phase. Figure 2 shows chro-
matograms of a blank sample, an extracted standard sample
with the R-(−)- and S-(+)-enantiomers of ondansetron and
8-hydroxyondansetron, and at least an authentic plasma
sample extract only containing racemic ondansetron. The
order of elution of the enantiomers was determined by sepa-
rately injecting solutions of each enantiomer. The linear
regression analysis yielded following equations:
R-(−)-ondansetron: y = 0.106x + (–1.49) (r = 1.0000)
S-(+)-ondansetron: y = 0.0555x + (–0.45) (r = 0.9998)
R-(−)-8-hydroxyondansetron: y = 0.0164x + (–0.254) (r = 0.9986)
S-(+)-8-hydroxyondansetron: y = 0.0342x + (0.148) (r = 0.9991)
The LODs of R-(−)- and S-(+)-ondansetron were 0.5 and 0.7
ng/mL with LOQs of 1.5 and 2.1 ng/mL. The LOD of R-(−)- and
S-(+)-8-hydroxyondansetron was 0.6 ng/mL with an LOQ of 1.8
ng/mL. Intraassay (n = 6) and interassay precision (n = 10; two
calibration curves during the study) showed acceptable values
with relative standard deviations (R.S.D.) of less than 10 % for
the high and middle control and less than 20% for the low con-
trol. For the ondansetron and 8-hydroxyondansetron enan-
tiomers the recovery was between 85 and 91% (n = 5). Ion sup-
pression and enhancement from plasma matrix was negligible
under present conditions (84–95%). The enantiomers and
metabolites were found to be stable in plasma at –20°C for 3
months, in the mobile phase at 20°C for 24 h, and during
three freeze/thaw cycles. No chiral inversion was observed at
25°C for 24 h during storage, processing, and analysis. To sum
up validation data were within international required limits
and the assay was successfully applied to authentic plasma
samples.
The analysis of 151 samples from patients routinely receiving
intravenous 4 mg racemic ondansetron revealed positive re-
sults for R-(−)- and S-(+)-ondansetron in all analyzed samples.
Without hydrolysis the main metabolite 8-hydroxyondansetron
was not detected in any of the analyzed samples. Mean and me-
dian plasma concentrations, the concentration ranges, and
the ratios S-(+)-/R-(–)-ondansetron are described in Table I.
These present results from postoperative patients receiving
ondansetron for postoperative treatment of PONV demon-
strated a great interindividual variability in drug concentra-
tions and, therefore, a wide therapeutic concentration range;
the body mass index was not helpful to understand such dif-
ferences in plasma concentrations. The measured concentra-
tions of both ondansetron enantiomers (sums) are in the range
described by others (13,22). According to previous reports free
8-hydroxyondansetron was not found in any case with an LOD
of 0.6 ng/mL; a hydrolysis prior to analysis was not performed
in the present study.
In general, large differences have been observed between
individuals in the capacity and speed of drug metabolism. This
variability may be due to concurrent diseases (e.g., renal
failure, impaired liver function), co-medications, environ-
mental pollutants that influence the enzymatic function of
specific isoenzymes as well as other factors. Further well-rec-
ognized variables are genetic polymorphisms of metabolising
enzymes or targets of drug action which can have a significant
impact on pharmacokinetic/pharmacodynamic of respective
drugs. Genetic variants of the cytochrome P450 (CYP) en-
zymes play a major role in pharmacokinetic variability and
can affect outcome in drug therapy. Individuals carrying alleles
reducing enzyme activity may have a phenotype that may me-
tabolize a given drug poorly [poor metabolizer (PM)] or at an
intermediate level [intermediate metabolizer (IM)] compared
to extensive metabolizers (EM) carrying two wild-type alleles.
A gene duplication or multiduplication can result in largely in-
creased enzyme activity resulting in the ultrarapid metabolizer
(UM) phenotype.
Considering ondansetron, there was no difference in the
AUC, Cmax, and t½ in healthy subjects between EMs (n = 6) and
PMs (n = 6) receiving a single dose (8 mg i.v.) (23). Otherwise,
it was demonstrated that CYP2D6 UMs experienced more vom-
iting compared to EMs or PMs when given ondansetron in the
treatment of chemotherapy-induced nausea and vomiting (24).
But this difference was predictably more pronounced for top-
isetron than ondansetron because topisetron is primarily de-
pendent on the CYP2D6 isoenzyme for metabolism. In a fur-
ther study of 250 patients undergoing standardized general
anesthesia UMs had increased therapeutic failure and a re-
duced response to ondansetron 4 mg (25). However, plasma
concentrations were not determined in this study.
Data on enantiomeric disposition of ondansetron are sparse.
Otherwise, stereoselective variations could be of interest in
individual cases because of different pharmacodynamic prop-
erties of both enantiomers. In general a stereoselectivity can be
assumed in the body distribution, the renal clearance, and
also in the hepatic metabolism of drugs.
In a stereoselective pharmacokinetic study involving four
healthy male Chinese, Liu et al. (21) found that the concen-
tration of R-(–)-ondansetron was higher than of S-(+)-
ondansetron at all the time points measured, implying a stere-
oselective disposition of ondansetron enantiomers. In contrast
to this study, the present investigation enrolling a large col-
lective of patients in a European hospital revealed interindi-
vidual differences in the concentration ratio of S-(+)-/R-(–)-
Table I. Plasma Concentrations of S-(+)- and R-(–)-
Ondansetron in 151 Plasma Samples from Postoperative
Patients
Sum
S-(+)- R-(–)- S-(+)- + R-(–)- Ratio
Ondansetron Ondansetron Ondansetron S-(+)-/R-(–)-
(ng/mL) (ng/mL) (ng/mL) Ondansetron
Mean 38.70 24.93 63.63 2.60
SD 11.59 21.21 22.57 1.52
Median 39.10 16.00 56.10 3.06
Min 8.04 4.15 33.95 0.14
Max 82.20 84.30 157.50 7.18
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ondansetron between 0.14 and 7.18. These different findings
could be explained by different study designs, volunteers
without any co-medication versus patients receiving various
drugs for anesthesia and suffering in part from diverse co-
morbidity, as well as varying geographic distributions and fre-
quencies of genetic variants in populations from different re-
gions of the world (26).
Considering these preliminary results, CYP2D6 and CYP3A
genotype dependent metabolism of ondansetron enantiomers
might be of specific interest, because effects on efficacy of
antiemetic treatment with ondansetron might be possible.
Meanwhile, CYP dependent metabolism of a large amount of
frequently used drugs is well described (27) with numerous re-
ports describing lacking efficacy, side effects, or even toxicity of
individual drugs. Multiple interactions in pharmacokinetics
resulting in adverse drug reactions (ADRs) and outcome in
drug treatment can be assumed (28).
In general, pharmacogenetics can help to individualize phar-
macotherapy and to improve care by predicting the optimal
dose and avoiding side effects and toxicity in individual patients
(29). Screening for variations in the expression of drug me-
tabolizing enzymes has been suggested as a potential tool for
improving therapy regimes (30,31). Further candidate genes
like receptors, transporters and other targets of pharma-
cotherapy are currently under investigation. Aspects of ge-
netic differences influencing efficacy, side effects and adverse
outcome of pharmacotherapy will be of importance for future
medication regimes.
Conclusions
A quantitative determination of ondansetron in human
plasma by enantioselective LC–MS–MS was achieved on a Chi-
ralcel OD-R column containing cellulose tris-(3,5-dimethyl-
phenylcarbamate). The method was fully validated and suc-
cessfully applied to authentic plasma samples. Quantitative
results from postoperative patients receiving ondansetron
demonstrated a great interindividual variability in plasma drug
concentrations and, therefore, a wide therapeutic concentra-
tion range. The main metabolite 8-hydroxyondansetron was
not detected in its unconjugated form. A wide variation in the
S-(+)-/R-(–)-ondansetron concentration ratio is indicative for
a stereoselective disposition or metabolism. In further studies,
CYP-dependent metabolism of ondansetron enantiomers and
clinical efficacy of the medication should be tested.
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